ArticleCancers2026
FAM64A Potentiates Bladder Carcinoma Tumorigenesis and Metastasis Through PI3K/mTORC2/AKT Pathway Activation.
Tao Zhu, Cen Liufu, Cong Yin, Jinqing He, Junhua Luo, Bentao Shi, Yan Wang
Abstract read
In one paragraphArticle in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Tao ZhuDepartment of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, China.
Cen LiufuDepartment of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, China.
Cong YinDepartment of Urology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518035, China.ORCID 0000-0001-6334-4677 Jinqing HeDepartment of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, China.
Junhua LuoDepartment of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, China.
Bentao ShiDepartment of Urology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518035, China.ORCID 0000-0003-3185-1740 Yan WangCentral Laboratory, Shenzhen Qianhai Taikang Hospital, No. 3099, Menghai Avenue, Nanshan District, Shenzhen 518000, China.
Funding
Shenzhen Clinical Research Center for Urology and Nephrology LCYSSQ20220823091403008the Science Technology and Innovation Commission of Shenzhen Municipality JCYJ20190809104411245the Science Technology and Innovation Commission of Shenzhen Municipality JCYJ20220531094207017the Science Technology and Innovation Commission of Shenzhen Municipality JCYJ20220531094217040the Scientific Research Foundation of Peking University Shenzhen Hospital KYQD2023308
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
bladder cancerEMTFAM64API3K/mTORC2/AKT
Identifiers
PMID41682010
PMCPMC12896460
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390